One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Committing to people experiencing homelessness
doi : 10.1016/S2215-0366(23)00041-X
Volume 10, Issue 3, March 2023, Page 155
Cautious optimism regarding the use of home-based neuromodulation to treat depression
doi : 10.1016/S2215-0366(23)00028-7
Volume 10, Issue 3, March 2023, Pages 156-157
Predicting psychotic relapse following paliperidone discontinuation
Takefumi Suzuki a
The relevance of long-acting injectables in the treatment of schizophrenia
Martina Hahn a b, Sibylle Christine Roll b
India's National Suicide Prevention Strategy: considerations to enhance desired outcomes
Rakhi Dandona a b, G Anil Kumar a
National Suicide Prevention Strategy of India: implementation challenges and the way forward
Ramdas Ransing a, S M Yasir Arafat b, Vikas Menon c, Sujita Kumar Kar d
Childhood trauma and disruptive mood dysregulation disorder
doi : 10.1016/S2215-0366(22)00433-3
Volume 10, Issue 3, March 2023, Page 166
Childhood trauma and disruptive mood dysregulation disorder – Authors' reply
doi : 10.1016/S2215-0366(23)00035-4
Volume 10, Issue 3, March 2023, Pages 166-167
Psychotherapy and psychedelic drugs
doi : 10.1016/S2215-0366(23)00024-X
Volume 10, Issue 3, March 2023, Pages 167-168
Psychotherapy and psychedelic drugs – Authors' reply
doi : 10.1016/S2215-0366(23)00029-9
Volume 10, Issue 3, March 2023, Page 168
Deborah Hasin: digging deeper into drug use disorders
Talha Burki
OCD, metaphor, and me: the horse that can’t eat apples
doi : 10.1016/S2215-0366(23)00040-8
Volume 10, Issue 3, March 2023, Pages 170-171
Clinical effectiveness of active Alpha-Stim AID versus sham Alpha-Stim AID in major depression in primary care in England (Alpha-Stim-D): a multicentre, parallel group, double-blind, randomised controlled trial
doi : 10.1016/S2215-0366(23)00007-X
Volume 10, Issue 3, March 2023, Pages 172-183
Predicting psychotic relapse following randomised discontinuation of paliperidone in individuals with schizophrenia or schizoaffective disorder: an individual participant data analysis
Lasse Brandt MD a, Prof Kerstin Ritter PhD a b, Johannes Schneider-Thoma MD c, Spyridon Siafis MD c, Christiane Montag MD a, Hakan Ayrilmaz HSD a, Prof Felix Bermpohl MD a d, Prof Alkomiet Hasan MD e, Prof Andreas Heinz PhD a b d, Prof Stefan Leucht MD c, Stefan Gutwinski MD a †, Heiner Stuke MD a f â€
Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST)
Inge Winter-van Rossum PhD a c, Prof Mark Weiser MD d, Prof Silvana Galderisi MD e, Prof Stefan Leucht MD f, Prof Istvan Bitter MD g, Prof Birte Glenthøj MD h i, Prof Alkomiet Hasan MD j, Jurjen Luykx MD a b k, Marina Kupchik MD l, Prof Georg Psota MD m, Prof Paola Rocca MD n, Prof Nikos Stefanis MD o, Prof Alexander Teitelbaum MD p, Mor Bar Haim d, Claudia Leucht MD f, Prof Georg Kemmler PhD q, Timo Schurr PhD q
Pharmacokinetics and pharmacogenomics of clozapine in an ancestrally diverse sample: a longitudinal analysis and genome-wide association study using UK clinical monitoring data
doi : 10.1016/S2215-0366(23)00002-0
Volume 10, Issue 3, March 2023, Pages 209-219
Creating positive experiences of involvement in mental health research
doi : 10.1016/S2215-0366(22)00430-8
Volume 10, Issue 3, March 2023, Pages 220-227
Catatonia in neurodevelopmental disorders: assessing catatonic deterioration from baseline
Aaron J Hauptman MD a b, Prof David Cohen MD c e, Prof Dirk Dhossche MD d, Marie Raffin MD e, Prof Lee Wachtel MD a b, Vladimir Ferrafiat MD f
